U.S. Markets close in 2 hrs 37 mins

Sigilon Therapeutics, Inc. (SGTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.25+2.53 (+8.51%)
As of 1:22PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close29.72
Open30.49
Bid31.73 x 800
Ask32.21 x 900
Day's Range30.01 - 32.83
52 Week Range22.00 - 54.32
Volume67,681
Avg. Volume170,664
Market Cap1.007B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.75
  • Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™
    GlobeNewswire

    Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™

    Results demonstrate potential of Company’s therapies developed using its novel Shielded Living Therapeutics™ platform to treat broad range of chronic diseasesCAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported results from several ongoing preclinical studies in a broad range of lysosomal diseases (LD) during the 17th Annual WORLDSymposium™, which is being held virtually from February 8-11. Four scientific abstracts were selected for presentation—including an oral presentation on MPS-2. “These data, which span four distinct lysosomal diseases—including MPS-1, Fabry, MPS-2 and MPS-6—demonstrate the potential of our novel Shielded Living Therapeutics platform to treat a broad range of chronic diseases,” said Rogerio Vivaldi MD, MBA, President & Chief Executive Officer at Sigilon. “The current standard of care for many lysosomal diseases includes enzyme replacement therapy or bone marrow transplant, both of which can result in suboptimal outcomes for patients due to inadequate distribution to some tissues and life-threatening complications, respectively.” Continued Dr. Vivaldi: “While these are early data, our novel therapeutic candidates—which are comprised of engineered human cells shielded within spheres designed to avoid immune rejection and fibrosis—demonstrated sustained release of the desired protein and an ability to reach multiple organ systems, regardless of disease. We believe the modularity of our platform may enable us to be effective in many disease areas and could support the rapid expansion of our candidates into the clinic. We remain highly encouraged by data generated to date as we continue to make significant progress with our platform in lysosomal diseases, with our lead program focused on MPS-1.” PRESENTATION DETAILS Oral Presentation Title: “SIG-018: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS II” (also presented as e-poster 254)Date/Time: Thursday, February 11th at 9:54 AM EST LIVE QA Session: 10:18 AM EST E-Poster PresentationsTitle: “SIG-005: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS I” (e-poster 060)Date: Thursday, February 11th LIVE QA Session: 2:30 PM EST Title: “SIG-007: Novel Encapsulated Non-Viral Cell-Based Therapy for Fabry disease” (e-poster 073)Date: Thursday, February 11th LIVE QA Session: 2:30 PM EST Title: “Development of a Novel Encapsulated Non-Viral Cell-Based Therapy for MPS VI” (e-poster 192)Date: Thursday, February 11th LIVE QA Session: 2:30 PM EST For more information and to access the presentations and Q&A sessions, please visit the WorldSymposium virtual platform. The abstracts will also be made available on the “Presentations” page of the “Science” section of the Sigilon corporate website at www.sigilon.com following the presentations. Additionally, please visit Sigilon’s booth in the virtual exhibit hall to learn more about the Company’s technology, commitment to patients and caregivers, and for more information on when and where to see Sigilon data at the conference. About Sigilon TherapeuticsSigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements relating to the modularity or potential of our platform technology and the preclinical and clinical development of our product candidates for the treatment of lysosomal storage diseases. Investors are cautioned not to place undue reliance on these forward-looking statements. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to our preclinical research, product candidates, the initiation and enrollment for our clinical trials and the regulatory filings related thereto and other risks identified in our SEC filings, including our Prospectus filed with the SEC on December 7, 2020 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CONTACT: Investor Contacts Glenn Reicin Sigilon Therapeutics, Chief Financial Officer glenn.reicin@sigilon.com 646-696-4344 Jennifer Porcelli Solebury Trout jporcelli@soleburytrout.com 646-378-2962 Media Contact Amy Bonanno Solebury Trout abonanno@troutgroup.com 914-450-0349

  • Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
    GlobeNewswire

    Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

    CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 14 at 3:40 p.m. EST, in a virtual format. A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of the webcast will be available following the event on the Sigilon website.About Sigilon Therapeutics Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.Investor Contacts Glenn Reicin Sigilon Therapeutics, Chief Financial Officer glenn.reicin@sigilon.com 646-696-4344Jennifer Porcelli Solebury Trout jporcelli@soleburytrout.com 646-378-2962Media Contact Amy Bonanno Solebury Trout abonanno@soleburytrout.com 914-450-0349

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For December 29, 2020

    Upgrades * For Continental Resources Inc (NYSE:CLR), KeyBanc upgraded the previous rating of Sector Weight to Overweight. Continental Resources earned $0.16 in the third quarter, compared to $0.54 in the year-ago quarter. The current stock performance of Continental Resources shows a 52-week-high of $36.20 and a 52-week-low of $6.90. Moreover, at the end of the last trading period, the closing price was at $16.26. Downgrades * For Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), Raymond James downgraded the previous rating of Outperform to Market Perform. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period. * According to HC Wainwright & Co., the prior rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) was changed from Buy to Neutral. In the third quarter, Arcturus Therapeutics showed an EPS of $0.92, compared to $0.56 from the year-ago quarter. The current stock performance of Arcturus Therapeutics shows a 52-week-high of $129.71 and a 52-week-low of $8.51. Moreover, at the end of the last trading period, the closing price was at $92.42. * For Aprea Therapeutics Inc (NASDAQ:APRE), RBC Capital downgraded the previous rating of Outperform to Sector Perform. For the third quarter, Aprea Therapeutics had an EPS of $0.58, compared to year-ago quarter EPS of $5.29. At the moment, the stock has a 52-week-high of $53.11 and a 52-week-low of $5.35. Aprea Therapeutics closed at $5.50 at the end of the last trading period. * Baird downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Outperform to Neutral. For the third quarter, Arcturus Therapeutics had an EPS of $0.92, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $8.51. Arcturus Therapeutics closed at $92.42 at the end of the last trading period. Initiations * Daiwa Capital initiated coverage on Splunk Inc (NASDAQ:SPLK) with a Neutral rating. In the third quarter, Splunk showed an EPS of $0.07, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of $225.89 and a 52-week-low of $93.92. At the end of the last trading period, Splunk closed at $175.55. * Morgan Stanley initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Equal-Weight rating. The price target for Sigilon Therapeutics is set to $45.00. At the moment, the stock has a 52-week-high of $54.32 and a 52-week-low of $22.00. Sigilon Therapeutics closed at $39.80 at the end of the last trading period. * With a Equal-Weight rating, Morgan Stanley initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $65.00 for Seer. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period. * SVB Leerink initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX) with an Outperform rating. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period. * With a Buy rating, Stifel initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $58.00 for Silverback Therapeutics. At the moment, the stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. Silverback Therapeutics closed at $36.50 at the end of the last trading period. * Evercore ISI Group initiated coverage on BeyondSpring Inc (NASDAQ:BYSI) with an Outperform rating. The price target for BeyondSpring is set to $30.00. In the third quarter, BeyondSpring showed an EPS of $0.48, compared to $0.37 from the year-ago quarter. The current stock performance of BeyondSpring shows a 52-week-high of $21.50 and a 52-week-low of $9.38. Moreover, at the end of the last trading period, the closing price was at $10.96. * Jefferies initiated coverage on Sigilon Therapeutics Inc (NASDAQ:SGTX) with a Buy rating. The price target for Sigilon Therapeutics is set to $60.00. The current stock performance of Sigilon Therapeutics shows a 52-week-high of $54.32 and a 52-week-low of $22.00. Moreover, at the end of the last trading period, the closing price was at $39.80. * With an Overweight rating, JP Morgan initiated coverage on Seer Inc (NASDAQ:SEER). The price target seems to have been set at $75.00 for Seer. The stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. At the end of the last trading period, Seer closed at $64.40. * For Seer Inc (NASDAQ:SEER), Cowen & Co. initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of $86.13 and a 52-week-low of $44.00. Seer closed at $64.40 at the end of the last trading period. * For Caesarstone Ltd (NASDAQ:CSTE), Benchmark initiated coverage, by setting the current rating at Buy. In the third quarter, Caesarstone showed an EPS of $0.41, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.86 and a 52-week-low of $7.65. Caesarstone closed at $10.80 at the end of the last trading period. * Benchmark initiated coverage on Porch Group Inc (NASDAQ:PRCH) with a Buy rating. The price target for Porch Group is set to $24.00. At the moment, the stock has a 52-week-high of $17.31 and a 52-week-low of $14.30. Porch Group closed at $14.71 at the end of the last trading period. * HC Wainwright & Co. initiated coverage on Tenax Therapeutics Inc (NASDAQ:TENX) with a Buy rating. The price target for Tenax Therapeutics is set to $5.00. In the third quarter, Tenax Therapeutics showed an EPS of $0.18, compared to $0.33 from the year-ago quarter. The stock has a 52-week-high of $2.68 and a 52-week-low of $0.25. At the end of the last trading period, Tenax Therapeutics closed at $1.07. * With a Buy rating, HC Wainwright & Co. initiated coverage on Silverback Therapeutics Inc (NASDAQ:SBTX). The price target seems to have been set at $44.00 for Silverback Therapeutics. The stock has a 52-week-high of $36.70 and a 52-week-low of $24.22. At the end of the last trading period, Silverback Therapeutics closed at $36.50.See more from Benzinga * Click here for options trades from Benzinga * Why Is It Moving? Analyzing The Upward Movement in BeyondSpring's Stock Today * Why Tenax Therapeutics's Stock is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.